Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL8170757 | 1.00 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL60725 | 0.95 | — | — | |
| Nitric Acid SCHEMBL8170759 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL16178481 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL11762449 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL136878 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL434245 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL7525228 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL612985 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL27857239 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420413-B2 | 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | LES LABORATOIRES SERVIER (FR) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | HSD3B2, HSD3B1, NR1H3 | CA5A 947/4885CA5B 709/4885MEN1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.